Fourth Quarter 2018 Net Sales of $19.0 Million,
Growth of 72% YoY on a GAAP Basis
Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company
(“Sientra” or the “Company”), announced today its financial results
for the fourth quarter and full year ended December 31, 2018.
Jeff Nugent, Chairman and Chief Executive
Officer of Sientra, commented, “Throughout 2018, we continued to
drive robust growth across the business, achieving record net sales
of $68.1 million and pro forma net sales growth of 46% compared to
full year 2017. In the fourth quarter, our sales grew 72%
year-over-year to $19.0 million, the highest quarterly net sales in
the company’s history, further demonstrating the underlying
momentum of the business and the benefits of Sientra’s
diversification strategy.”
Mr. Nugent added, “In our first full year with
miraDry, we fully integrated the business, invested strategically
in its commercial organization, launched the improved miraDry fresh
procedure protocol, and reported four consecutive quarters of
sequential net sales growth. With regards to Breast Products, we
achieved numerous milestones in 2018, all of which demonstrate our
commitment to patient safety and continued innovation for the
benefit of our plastic surgeon partners and their patients. In
addition to FDA’s approval of Sientra’s PMA supplement for our new
Wisconsin facility, we launched the industry-leading Sientra
Platinum20™ warranty, which is grounded in the strong confidence we
have in our 10-year clinical data. We also opened our
state-of-the-art Sientra Lab and Innovation Center of Excellence
(SLICE) and submitted our breast implant Medical Device License
Application to Health Canada.”
Mr. Nugent concluded, “Last year’s
accomplishments were pivotal to positioning Sientra for sustainable
long-term growth across both our business segments. I am encouraged
by the progress we have made in establishing Sientra as a leading,
diversified global partner to aesthetic physicians and I am looking
forward to continuing this momentum in 2019.”
Fourth Quarter and Full Year 2018
Financial ReviewTotal net sales for the fourth quarter
2018 were $19.0 million, an increase of 72% compared to total net
sales of $11.1 million for the same period in 2017. Total net sales
for full year 2018 of $68.1 million increased 86% compared to GAAP
net sales of $36.5 million for 2017 and 46% compared to pro forma
net sales of $46.7 million for 2017. Pro forma net sales assume the
miraDry acquisition was completed on January 1, 2017.
Net sales for the Breast Products segment
totaled $10.4 million in the fourth quarter 2018, a 28% increase
compared to $8.2 million for fourth quarter 2017. Net sales for the
Breast Products segment totaled $37.0 million for the full year
2018, representing an 18% increase compared to $31.5 million for
the full year 2017. Breast Products sales growth was primarily
driven by the continued improvement in implant supply levels and
the strong performance of the tissue expander portfolio.
Net sales for the miraDry segment totaled $8.6
million in the fourth quarter 2018, a 196% increase compared to
$2.9 million for the fourth quarter 2017. miraDry net sales for
full year 2018 of $31.1 million increased 515% compared to GAAP net
sales of $5.1 million for 2017 and 104% compared to pro forma net
sales of $15.3 million for 2017. miraDry sales growth was primarily
driven by strong system placements and consumables growth
internationally as well as continued traction in the United
States.
Gross profit for the fourth quarter 2018 was
$11.4 million, or 59.7% of sales, compared to gross profit of $5.3
million, or 48.1% of sales, for the same period in 2017. Gross
profit for the full year 2018 was $41.3 million, or 60.6% of sales,
compared to gross profit of $22.4 million, or 61.2% of sales, for
full year 2017. Changes in consolidated gross margin were driven by
the overall mix between Breast Products and miraDry, as well as the
geographic and capital versus consumable mix within miraDry.
Operating expenses for the fourth quarter 2018
were $35.7 million, compared to $22.7 million of expenses for the
same period in 2017. For the full year 2018, operating expenses
were $121.1 million, compared to $85.3 million of expenses for full
year 2017. Operating expenses for the quarter increased due to
investments in sales and marketing supporting the progress achieved
in scaling the miraDry commercial organization.
Net loss for the fourth quarter 2018 was ($24.6)
million, or ($0.86) per share, compared to a net loss of ($17.8)
million, or ($0.92) per share, for the same period in 2017. Net
loss for the full year of 2018 was ($82.6) million, or ($3.25) per
share, compared to a net loss of ($64.0) million, or ($3.34) per
share, for the same period in 2017.
On a non-GAAP basis, the Company reported an
adjusted EBITDA loss of ($19.5) million and ($60.0) million
for the fourth quarter and full year 2018, respectively, compared
to a loss of ($13.9) million and ($41.0) million for the
fourth quarter and full year 2017, respectively. The year-over-year
change in adjusted EBITDA loss can primarily be attributed to the
inclusion of miraDry for the full year of 2018.
Net cash and cash equivalents as of December 31,
2018 were $86.9 million, compared to $103.0 million at the end of
third quarter 2018.
Conference CallSientra will
hold a conference call today, March 12, 2019 at 4:30 p.m. ET / 1:30
p.m. PT to discuss the results.
The dial-in numbers are (844) 464-3933 for
domestic callers and (765) 507-2612 for international callers. The
conference ID is 6538838. A live webcast of the conference call
will be available on the Investor Relations section of the
Company's website at www.sientra.com.
A replay of the call will be available starting
on March 12, 2019 at 7:30 p.m. ET / 4:30 p.m. PT, through March 19,
2019 at 11:59 p.m. ET / 8:59 p.m. PT. To access the replay,
dial (855) 859-2056 for domestic callers and (404) 537-3406 for
international callers and use the replay conference ID 6538838. The
webcast will be available on the Investor Relations section of the
Company’s website for 30 days following the completion of the call.
Use of Non-GAAP Financial
MeasuresSientra has supplemented its US GAAP net
income (loss) with a non-GAAP measure of Adjusted EBITDA.
Management believes that this non-GAAP financial measure provides
useful supplemental information to management and investors
regarding the performance of the Company, facilitates a more
meaningful comparison of results for current periods with previous
operating results, and assists management in analyzing future
trends, making strategic and business decisions and establishing
internal budgets and forecasts. A reconciliation of non-GAAP
Adjusted EBITDA to GAAP net income (loss), the most directly
comparable GAAP measure, is provided in the schedule below.
There are limitations in using this non-GAAP
financial measure because it is not prepared in accordance with
GAAP and may be different from non-GAAP financial measures used by
other companies. This non-GAAP financial measure should not be
considered in isolation or as a substitute for GAAP financial
measures. Investors and potential investors should consider
non-GAAP financial measures only in conjunction with Sientra’s
financial statements prepared in accordance with GAAP and the
reconciliations of the non-GAAP financial measure provided in the
schedule below.
About SientraHeadquartered in
Santa Barbara, California, Sientra is a diversified global medical
aesthetics company and a leading partner to aesthetic physicians.
The Company offers a suite of products designed to make a
difference in patients' lives by enhancing their body image,
growing their self-esteem, and restoring their confidence. Sientra
has developed a broad portfolio of products with technologically
differentiated characteristics, supported by independent laboratory
testing and strong clinical trial outcomes. The
Company’s Breast Products Segment includes its OPUS™ breast
implants, the first fifth generation breast implants approved by
the FDA for sale in the United States, its ground-breaking Allox2®
breast tissue expander with patented dual-port and integral drain
technology, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons(*). The Company’s
miraDry Segment, comprises its miraDry® system, which is approved
for sale in over 40 international markets, and is the only
non-surgical FDA-cleared device for the permanent reduction of
underarm sweat, odor and hair of all colors.
(*) Data on file
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
based on management’s current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and actual
results may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements include, but are not limited to,
statements regarding the Company’s expected net sales for the
quarter ended December 31, 2018, the Company’s expected cash and
cash equivalents as of December 31, 2018, the expected growth of
the Company’s current customer base and acquisition of new
customers, and the Company’s ability to achieve sustainable,
long-term growth across its business segments. Such statements are
subject to risks and uncertainties, including the dependence on
conclusion of the audit procedures for the year ended December 31,
2018 by the Company’s independent auditors, positive reaction from
plastic surgeons and their patients to Sientra’s Breast Products,
the ability to meet consumer demand, the acceptance and growth of
its miraDry segment. Additional factors that could cause
actual results to differ materially from those contemplated in this
press release can be found in the Risk Factors section of Sientra’s
public filings with the Securities and Exchange Commission.
All statements other than statements of historical fact are
forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’
‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘
continue,’’ ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements.
Estimates, projections and other forward-looking statements speak
only as of the date they were made, and, except to the extent
required by law, the Company undertakes no obligation to update or
review any estimate, projection or forward-looking statement.
Investor Contact:
Neil Bhalodkar (805) 679-8845 ir@sientra.com
Sientra, Inc |
|
Consolidated Statements of
Operations |
|
(In thousands, except per share and share
amounts) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
Year EndedDecember
31, |
|
|
2018 |
|
|
2017 |
|
|
2018 |
|
|
2017 |
|
Net sales |
$ |
19,022 |
|
|
$ |
11,065 |
|
|
$ |
68,126 |
|
|
$ |
36,542 |
|
Cost of goods sold |
|
7,668 |
|
|
|
5,744 |
|
|
|
26,822 |
|
|
|
14,171 |
|
Gross
profit |
|
11,354 |
|
|
|
5,321 |
|
|
|
41,304 |
|
|
|
22,371 |
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and
marketing |
|
21,725 |
|
|
|
12,810 |
|
|
|
67,715 |
|
|
|
33,911 |
|
Research
and development |
|
3,015 |
|
|
|
2,136 |
|
|
|
10,945 |
|
|
|
9,813 |
|
General
and administrative |
|
10,999 |
|
|
|
7,784 |
|
|
|
42,418 |
|
|
|
31,537 |
|
Legal
settlement |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,000 |
|
Total
operating expenses |
|
35,739 |
|
|
|
22,730 |
|
|
|
121,078 |
|
|
|
85,261 |
|
Loss from
operations |
|
(24,385 |
) |
|
|
(17,409 |
) |
|
|
(79,774 |
) |
|
|
(62,890 |
) |
Other income (expense),
net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income |
|
318 |
|
|
|
60 |
|
|
|
532 |
|
|
|
172 |
|
Interest
expense |
|
(954 |
) |
|
|
(629 |
) |
|
|
(3,428 |
) |
|
|
(1,232 |
) |
Other
income (expense), net |
|
386 |
|
|
|
56 |
|
|
|
39 |
|
|
|
(95 |
) |
Total
other income (expense), net |
|
(250 |
) |
|
|
(513 |
) |
|
|
(2,857 |
) |
|
|
(1,155 |
) |
Loss
before income taxes |
|
(24,635 |
) |
|
|
(17,922 |
) |
|
|
(82,631 |
) |
|
|
(64,045 |
) |
Income tax benefit |
|
(4 |
) |
|
|
(88 |
) |
|
|
(4 |
) |
|
|
(17 |
) |
Net
loss |
$ |
(24,631 |
) |
|
$ |
(17,834 |
) |
|
$ |
(82,627 |
) |
|
$ |
(64,028 |
) |
Basic and diluted net
loss per share attributable to common stockholders |
$ |
(0.86 |
) |
|
$ |
(0.92 |
) |
|
$ |
(3.25 |
) |
|
$ |
(3.34 |
) |
Weighted average
outstanding common shares used for net loss per share attributable
to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and
diluted |
|
28,623,232 |
|
|
|
19,394,281 |
|
|
|
25,402,241 |
|
|
|
19,159,057 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017
includes the results of miraDry as of the acquisition date of
7/25/2017 |
|
|
|
Sientra, Inc |
|
Condensed Consolidated Balance
Sheets |
|
(In thousands) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
December 31, |
|
|
2018 |
|
|
2017 |
|
Assets |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and
cash equivalents |
$ |
86,899 |
|
|
$ |
26,588 |
|
Accounts
receivable, net |
|
22,527 |
|
|
|
6,569 |
|
Inventories, net |
|
24,085 |
|
|
|
20,896 |
|
Prepaid
expenses and other current assets |
|
2,612 |
|
|
|
1,512 |
|
Total
current assets |
|
136,123 |
|
|
|
55,565 |
|
Property and equipment,
net |
|
2,536 |
|
|
|
4,763 |
|
Goodwill |
|
12,507 |
|
|
|
12,507 |
|
Other intangible
assets, net |
|
16,495 |
|
|
|
18,803 |
|
Other assets |
|
698 |
|
|
|
575 |
|
Total
assets |
$ |
168,359 |
|
|
$ |
92,213 |
|
Liabilities and
Stockholders' Equity |
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
Current
portion of long-term debt |
$ |
6,866 |
|
|
$ |
24,639 |
|
Accounts
payable |
|
13,184 |
|
|
|
5,811 |
|
Accrued
and other current liabilities |
|
27,697 |
|
|
|
13,474 |
|
Legal
settlement payable |
|
410 |
|
|
|
1,000 |
|
Customer
deposits |
|
9,936 |
|
|
|
5,423 |
|
Sales
return liability |
|
6,048 |
|
|
|
— |
|
Total
current liabilities |
|
64,141 |
|
|
|
50,347 |
|
Long-term debt, net of
current portion |
|
27,883 |
|
|
|
— |
|
Deferred and contingent
consideration |
|
6,481 |
|
|
|
12,597 |
|
Warranty reserve and
other long-term liabilities |
|
2,976 |
|
|
|
1,646 |
|
Total
liabilities |
|
101,481 |
|
|
|
64,590 |
|
Stockholders'
equity: |
|
|
|
|
|
|
|
Total
stockholders' equity |
|
66,878 |
|
|
|
27,623 |
|
Total
liabilities and stockholders' equity |
$ |
168,359 |
|
|
$ |
92,213 |
|
|
|
|
|
|
|
|
|
Sientra, Inc |
|
Condensed Consolidated Statements of Cash
Flows |
|
(In thousands) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended |
|
|
December 31, |
|
|
2018 |
|
|
2017 |
|
Cash flows from
operating activities: |
|
|
|
|
|
|
|
Net
loss |
$ |
(82,627 |
) |
|
$ |
(64,028 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
3,321 |
|
|
|
3,034 |
|
Provision
for doubtful accounts |
|
2,043 |
|
|
|
493 |
|
Provision
for warranties |
|
325 |
|
|
|
294 |
|
Provision
for inventory |
|
955 |
|
|
|
3,125 |
|
Amortization of acquired inventory step-up |
|
106 |
|
|
|
999 |
|
Change in
fair value of warrants |
|
(81 |
) |
|
|
95 |
|
Change in
fair value of deferred consideration |
|
24 |
|
|
|
(110 |
) |
Change in
fair value of contingent consideration |
|
2,528 |
|
|
|
1,135 |
|
Change in
deferred revenue |
|
627 |
|
|
|
— |
|
Non-cash
portion of debt extinguishment loss |
|
— |
|
|
|
17 |
|
Amortization of debt discount and issuance costs |
|
174 |
|
|
|
140 |
|
Non-cash
interest expense |
|
— |
|
|
|
1 |
|
Stock-based compensation expense |
|
13,824 |
|
|
|
6,766 |
|
Loss on
disposal of property and equipment |
|
74 |
|
|
|
25 |
|
Deferred
income taxes |
|
(8 |
) |
|
|
(21 |
) |
Payments
of contingent consideration liability in excess of acquisition-date
fair value |
|
(320 |
) |
|
|
— |
|
Changes
in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts
receivable |
|
(14,094 |
) |
|
|
(1,890 |
) |
Inventories |
|
(4,250 |
) |
|
|
527 |
|
Prepaid
expenses, other current assets and other assets |
|
(1,302 |
) |
|
|
674 |
|
Insurance
recovery receivable |
|
39 |
|
|
|
9,336 |
|
Accounts
payable |
|
8,502 |
|
|
|
1,290 |
|
Accrued
and other liabilities |
|
7,885 |
|
|
|
3,218 |
|
Legal
settlement payable |
|
(590 |
) |
|
|
(9,900 |
) |
Customer
deposits |
|
4,513 |
|
|
|
(1,136 |
) |
Sales
return liability |
|
2,142 |
|
|
|
— |
|
Net Cash
Flow from Operating Activities |
|
(56,190 |
) |
|
|
(45,916 |
) |
Cash flows from
investing activities: |
|
|
|
|
|
|
|
Purchase
of property and equipment |
|
(855 |
) |
|
|
(1,864 |
) |
Business
acquisitions, net of cash acquired |
|
— |
|
|
|
(18,455 |
) |
Net Cash
Flow from Investing Activities |
|
(855 |
) |
|
|
(20,319 |
) |
Cash flows from
financing activities: |
|
|
|
|
|
|
|
Net
proceeds from issuance of common stock |
|
107,551 |
|
|
|
— |
|
Proceeds
from exercise of stock options |
|
1,149 |
|
|
|
1,346 |
|
Proceeds
from issuance of common stock under ESPP |
|
993 |
|
|
|
647 |
|
Tax payments related to shares withheld for vested restricted stock units (RSUs) |
|
(1,635 |
) |
|
|
(725 |
) |
Gross
borrowings under the Term Loan |
|
10,000 |
|
|
|
25,000 |
|
Gross
borrowings under the Revolving Loan |
|
12,109 |
|
|
|
5,000 |
|
Repayment
of the Revolving Loan |
|
(12,109 |
) |
|
|
(5,000 |
) |
Payments
of contingent consideration up to acquisition-date fair value |
|
(680 |
) |
|
|
— |
|
Deferred
financing costs |
|
(22 |
) |
|
|
(657 |
) |
Net Cash
Flow from Financing Activities |
|
117,356 |
|
|
|
25,611 |
|
Net
Increase (Decrease) in Cash |
|
60,311 |
|
|
|
(40,624 |
) |
Cash and cash
equivalents at: |
|
|
|
|
|
|
|
Beginning
of period |
|
26,588 |
|
|
|
67,212 |
|
End of
period |
$ |
86,899 |
|
|
$ |
26,588 |
|
|
|
|
|
|
|
|
|
2017
includes the results of miraDry as of the acquisition date of
7/25/2017 |
|
|
|
Sientra, Inc. |
|
Reconciliation of Net Loss to Non-GAAP
Adjusted EBITDA |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
Year EndedDecember
31, |
|
Dollars, in
thousands |
2018 |
|
|
2017 |
|
|
2018 |
|
|
2017 |
|
Net loss, as
reported |
$ |
(24,631 |
) |
|
$ |
(17,832 |
) |
|
$ |
(82,627 |
) |
|
$ |
(64,028 |
) |
Adjustments to net
loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
(income) expense and other, net |
|
250 |
|
|
|
513 |
|
|
|
2,857 |
|
|
|
1,155 |
|
Provision
for income taxes |
|
(4 |
) |
|
|
(88 |
) |
|
|
(4 |
) |
|
|
(17 |
) |
Depreciation and amortization |
|
821 |
|
|
|
1,194 |
|
|
|
3,427 |
|
|
|
4,033 |
|
Accretion
in fair value adjustments to contingent consideration |
|
350 |
|
|
|
363 |
|
|
|
2,528 |
|
|
|
1,135 |
|
Stock-based compensation |
|
3,748 |
|
|
|
1,989 |
|
|
|
13,824 |
|
|
|
6,766 |
|
Legal
settlement expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,000 |
|
Total
adjustments to net loss |
|
5,165 |
|
|
|
3,971 |
|
|
|
22,632 |
|
|
|
23,072 |
|
Adjusted EBITDA |
$ |
(19,466 |
) |
|
$ |
(13,861 |
) |
|
$ |
(59,995 |
) |
|
$ |
(40,956 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
Year EndedDecember
31, |
|
As a Percentage
of Revenue** |
2018 |
|
|
2017 |
|
|
2018 |
|
|
2017 |
|
Net loss, as
reported |
|
(129.5 |
%) |
|
|
(161.2 |
%) |
|
|
(121.3 |
%) |
|
|
(175.2 |
%) |
Adjustments to net
loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
(income) expense and other, net |
|
1.3 |
% |
|
|
4.6 |
% |
|
|
4.2 |
% |
|
|
3.2 |
% |
Provision
for income taxes |
|
(0.0 |
%) |
|
|
(0.8 |
%) |
|
|
(0.0 |
%) |
|
|
(0.0 |
%) |
Depreciation and amortization |
|
4.3 |
% |
|
|
10.8 |
% |
|
|
5.0 |
% |
|
|
11.0 |
% |
Accretion
in fair value adjustments to contingent consideration |
|
1.8 |
% |
|
|
3.3 |
% |
|
|
3.7 |
% |
|
|
3.1 |
% |
Stock-based compensation |
|
19.7 |
% |
|
|
18.0 |
% |
|
|
20.3 |
% |
|
|
18.5 |
% |
Legal
settlement expense |
|
0.0 |
% |
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
27.4 |
% |
Total
adjustments to net loss |
|
27.2 |
% |
|
|
35.9 |
% |
|
|
33.2 |
% |
|
|
63.1 |
% |
Adjusted EBITDA |
|
(102.3 |
%) |
|
|
(125.3 |
%) |
|
|
(88.1 |
%) |
|
|
(112.1 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017
includes the results of miraDry as of the acquisition date of
7/25/2017 |
|
**
Adjustments may not add to the total figure due to rounding |
|
|
|
Sientra, Inc. |
|
Pro Forma Net Sales |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
Year EndedDecember
31, |
|
Dollars, in
thousands |
2018 |
|
|
2017 |
|
|
2018 |
|
|
2017 |
|
Net sales - pro
forma |
$ |
19,022 |
|
|
$ |
11,065 |
|
|
$ |
68,126 |
|
|
$ |
46,747 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Sep 2023 to Sep 2024